Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma. It is not known if there are differences in outcome between early versus delayed BEV treatment of recurrent glioblastoma. We examined the relationship between the time of starting BEV treatment and outcomes in pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Neurooncol
Autores principales: Hamza, Mohamed A., Mandel, Jacob J., Conrad, Charles A., Gilbert, Mark R., Yung, W. K. Alfred, Puduvalli, Vinay K., DeGroot, John F.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297475/
https://ncbi.nlm.nih.gov/pubmed/24803001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1460-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares